Cohance Lifesciences Limited
COHANCE
株式のランク
#6352
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a... Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
株価
$5.09
時価総額
$1.95B
変化（1日）
0.79%
変化（1年）
-57.04%
国
IN
取引 Cohance Lifesciences Limited (COHANCE)
カテゴリー
Healthcare
Cohance Lifesciences Limited（COHANCE）の収益
Jun 2025 時点の収益 TTM: $176.91M
Cohance Lifesciences Limited の最新の財務報告によると、現在の収益 (TTM) は $176.91M です。2024 年には $126.09M の収益があり、これは 2023 年の $163.10M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cohance Lifesciences Limited の収益履歴（2019 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $176.91M | 26.34% |
| 2025 | $140.02M | 11.05% |
| 2024 | $126.09M | -22.69% |
| 2023 | $163.10M | -4.01% |
| 2022 | $169.91M | 26.93% |
| 2021 | $133.86M | 24.97% |
| 2020 | $107.11M | 103.08% |
| 2019 | $52.74M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 3,637.27% |
IN
|
